Background: Ovarian cancer is associated with poor survival, because patients are diagnosed at an advanced stage of the disease, and in addition, tumors develop chemoresistance, which carries a poor prognosis for the patient.
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. High expression levels of this antiapoptotic protein have been previously found in epithelial carcinomas located in the gastrointestinal tract (Kawasaki et al, 1998; Sarela et al, 2000) , breast (Tanaka et al, 2000) , lung (Monzo et al, 1999) , and ovary (Sui et al, 2002; Takai et al, 2002) , and associated with increased biological aggressiveness, elevated proliferative activity, and several unfavorable prognostic parameters, such as increased stage or reduced survival.
Smac, also known as direct inhibitor of apoptosis binding protein with low isoelectric point (DIABLO), is a mithochondrial protein containing an NHterminal SS-amino-acid mitochondrial import sequence, released from mitochondria into the cytosol in response to apoptotic stimuli (Du et Mitochondrial Smac release is suppressed by Bcl-2 and Bcl-XL (Vyas et al, 2004) .
In this study, we investigate whether the expression of SDF-1, survivin, and smac correlate with clinical characteristics and cancer-specific survival of patients. and 25 normal ovaries tissues (NO) ( Table 1) . Fresh surgical specimens were collected between May 2013 and December 2014, snap-frozen in liquid nitrogen immediately after resection, and were stored at −80 °C for immunohistochemistry analysis. The clinical and pathological characteristics of these patients are described in Tables 1 and 2 . The patients were staged according to the International Federation of Gynecology and Obstetrics (FIGO). All tissue blocks were reviewed for histological type and graded by two senior pathologists, stained with hematoxylin-eosin. The study protocols have been approved by the local Ethics Committee.
Materials and methods

Samples
Prior informed consent was obtained from the patients according to the Declaration of Helsinki. tumor cells were stained more than 1%, the case was considered as the positive. For the analysis of the correlation between biomarkers, immunohistochemical score was calculated by multiplying the intensity score (0 to 3) and fraction score (0 to 100).
Immunohistochemical findings were correlated with clinicopathological characteristics such as stage, histologic grade, lymph node metastasis, and ascites.
Statistical methods
Statistical analyses were performed using the SPSS 15.0 statistical software package. Correlations between SDF-1, surviving and smac expression and the clinicopathologic parameters were evaluated by χ 2 test. Correlations between various factors were assessed by Spearman rank correlations. The criterion for inclusion of a variable was p < 0.05 in the univariate analysis and for removing a variable p > 0.05 in the multivariate analysis.
Results
We performed immunohistochemical staining to analyze the expression of SDF-1, survivin and smac in 25 normal ovaries, 40 benign tumors, and 60 EOC. Representative samples of SDF-1, survivin and smac staining are displayed in Table 1 . SDF-1, survivin and smac positive staining predominantly showed cytoplasmic and membrane localization, and EOC specimens were strongly positive for SDF-1, and survivin expression. In contrast, SDF-1, and survivin immunoreactivity was negatively or weakly observed in the normal and benign tumors.
Differences in proportions were evaluated by χ 2 or Fisher's test, whichever is appropriate. The SPSS statistical software system for Windows (Statistical Package for Social Sciences, version 10.0, Chicago, IL, USA) was used for the statistical analysis. P < 0.05 was considered to be statistically significant. Table 2 , SDF-1 expressions were significantly more weaker in advanced ovarian carcinomas (FIGO stage III-IV), and in high-grade carcinomas. FIGO stage and histological grade were not associated with SDF-1 staining (P > 0.05). In contrast, SDF-1 expressions were significantly stronger in EOC patients with lymph node metastasis and with ascites. There was a positive correlation between EOC patients with lymph node metastasis and with ascites and SDF-1 positivity (P < 0.05). Survivin expressions were significantly more stronger in advanced ovarian carcinomas (FIGO stage III-IV), and in high-grade carcinomas. FIGO stage and histological grade were positively associated with surviving positivity (P < 0.05). In addition, survivin expressions were significantly stronger in EOC patients with lymph node metastasis and with ascites. There was a positive correlation between EOC patients with lymph node metastasis and with ascites and surviving positivity (P < 0.05, Table 2 ).
As indicated in
Smac expressions were significantly more stronger in advanced ovarian carcinomas (FIGO stage III-IV), and in high-grade carcinomas. FIGO stage and histological grade were positively associated with smac positivity (P < 0.05). In addition, smac expressions were significantly stronger in EOC patients with lymph node metastasis and with ascites. There was a positive correlation between EOC patients with lymph node metastasis and with ascites and smac positivity (P < 0.05, Table 2 ).
Discussion
The purpose of the present study was to investigate the prognostic significance of SDF-1, survivin and smac expression in There may be such contradictory observations because in these studies SDF-1 expression was detected by immunohistochemistry and, thus, they did not distinguish which SDF-1 isoform was responsible for the observed higher SDF-1 protein expression. SDF-1 expression in cancer is also epigenetically regulated by promoter methylation and SDF-1 gene polymorphism probably increases In our current study, SDF-1, surviving and smac expressions are strong in EOC patients, indicating that SDF-1, surviving and smac are closely associated with EOC development. In addition, statistical analysis shows that FIGO stage and histological grade were not associated with SDF-1 staining (P > 0.05). However, FIGO stage and histological grade were positively associated with surviving and smac staining (P > 0.05). There was a positive correlation between EOC patients with lymph node metastasis and with ascites and SDF-1, surviving or smac positivity (P < 0.05). These results indicate that surviving and smac are correlated with clinical stage and lymph node metastasis of EOC patients.
